Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?

Gynecologic Oncology

Volumn 128, Issue 3, 2013, Pages 579-583

  Angioli, Roberto ^a   Plotti, Francesco ^a   Capriglione, Stella ^a   Aloisi, Alessia ^a   Montera, Roberto ^a   Luvero, Daniela ^a   Miranda, Andrea ^a   Cafà, Ester Valentina ^a   Damiani, Patrizio ^a   Benedetti Panici, Pierluigi ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Advanced ovarian cancer; CA125; HE4; Optimal cytoreduction; Predictive value; Preoperative HE4

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; HE4 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; FEMALE; GYNECOLOGIC SURGERY; HUMAN; HYSTERECTOMY; LAPAROSCOPY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; SENSITIVITY AND SENSIBILITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROTEINS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84873728934     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.11.040     Document Type: Article

References (33)

1. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 5 2002 1248 1259
2. W.J. Hoskins, W.P. McGuire, M.F. Brady, H.D. Homesley, W.T. Creasman, and M. Berman The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am J Obstet Gynecol 170 1994 974 979
3. I. Vergote Role of surgery in ovarian cancer: an update Acta Chir Belg 104 3 2004 246 256
4. S.M. Eisenkop, R.L. Friedman, and H.J. Wang Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer Gynecol Oncol 69 1998 103 108
5. R. Angioli, I. Palaia, M.A. Zullo, L. Muzii, N. Manci, and M. Calcagno Diagnostic open laparoscopy in the management of advanced ovarian cancer Gynecol Oncol 100 3 Mar 2006 455 461
6. A. Fagotti, F. Fanfani, M. Ludovisi, R. Lo Voi, G. Bifulco, and A. Testa Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study Gynecol Oncol 96 2005 729 735
7. A. Quayyum, F.V. Coakley, A.C. Westphalen, H. Hricak, W.T. Okuno, and B. Powell Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer Gynecol Oncol 96 2 2005 301 306 [9]
8. S.C. Dowdy, S.A. Mullany, K.R. Brandt, B.J. Huppert, and W.A. Cliby The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma Cancer 101 2 2004 346 352
9. B.E. Nelson, A.T. Rosenfield, and P.E. Schwartz Preoperative abdominopelvic computed 420 tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma J Clin Oncol 11 1993 166 172
10. D. Chi, E. Venkatraman, V. Masson, and W. Hoskins The ability of preoperativeserum Ca-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma Gynecol Oncol 77 2 2000 227 231
11. U. Saygili, S. Guclu, T. Uslu, O. Erten, N. Demir, and A. Onvural Can serum Ca-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol 86 1 2002 57 61
12. S. Memarzadeh, S.B. Lee, J.S. Berek, and R. Farias-Eisner Ca-125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer Int J Gynecol Cancer 13 2 2003 120 124
13. B. Obeidat, J. Latimer, and R. Crawford Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum Ca-125 level Gynecol Obstet Invest 57 3 2004 153 156
14. O. Gemer, S. Segal, and A. Kopmar Preoperative Ca-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer Acta Obstet Gynecol Scand 80 6 2001 583 585
15. E.C. Brockbank, T.E. Ind, D.P. Barton, J.H. Shepherd, M.E. Gore, and R. A'Hern Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer Int J Gynecol Cancer 14 1 2004 42 50
16. G.H. Eltabbakh, S.L. Mount, B. Beatty, L. Simmons-Arnold, K. Cooper, and A. Morgan Factors associated with cytoreducibility among women with ovarian carcinoma Gynecol Oncol 95 2 2004 377 383
17. B.C. Cooper, A.K. Sood, C.S. Davis, J.M. Ritchie, J.L. Sorosky, and E. Anderson Preoperative Ca-125 levels: an independent prognostic factor for epithelial ovarian cancer Obstet Gynecol 100 1 2002 59 64
18. O. Gemer, M. Lurian, M. Gdalevich, V. Kapustian, E. Piura, and D. Schneider A multicenter study of Ca-125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer Eur J Surg Oncol 31 9 2005 1006 1010
19. T.S. Barlow, M. Przybylski, J.M. Schilder, D.H. Moore, and K.Y. Look The utility of presurgical Ca-125 to predict optimal tumor cytoreduction of epithelial ovarian cancer Int J Gynecol Cancer 16 2 2006 496 500
20. M.M. Gilani, M. Karimi Zarchi, F. Ghaemmaghami, N. Behtash, A.S. Mousavi, and S. Ansaripoor A study to evaluate the utility of presurgical Ca-125 to predict optimal tumor cytoreduction of epithelial ovarian cancer Gynecol Oncol 105 3 2007 70 783
21. A.H.M.M. Arits, J.E.G.M. Stoot, A.A.M. Botterweck, F.J.M.E. Roumen, and A.C. Voogd Preoperative serum Ca-125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer Int J Gynecol Cancer 18 4 2008 621 628
22. Hala A. Abdel-Azeez, Hany A. Labib, Samar M. Sharaf, and Ashraf N. Refaie HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses Asian Pac J Cancer Prev 2010 111 116
23. F. Plotti, S. Capriglione, C. Terranova, R. Montera, A. Aloisi, and P. Damiani Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol 33 6 2012 Dec 2117 2123
24. L. Muzii, F. Bellati, N. Manci, M.A. Zullo, R. Angioli, and P.B. Panici Ringer's lactate solution remains in the peritoneal cavity after laparoscopy longer than expected Fertil Steril 84 1 Jul 2005 148 153
25. FIGO cancer committee: staging announcement Gynecol Oncol 25 1986 383 385
26. I. Vergote, C.G. Tropé, F. Amant, G.B. Kristensen, T. Ehlen, and N. Johnson Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 10 Sep 2 2010 943 953
27. R. Bristow, L. Duska, and N. Lambrou A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography Cancer 89 2000 1532 1540
28. J. Meyer, A. Kennedy, R. Friedman, A. Ayoub, and R. Zepp Ovarian carcinoma: value of CT in preediting success of debulking surgery AJR Am J Roentgenol 165 1995 875 878
29. A.E. Axtell, M.H. Lee, R.E. Bristow, S.C. Dowdy, W.A. Cliby, and S. Raman Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer J Clin Oncol 25 4 Feb 1 2007 384 389
30. A. Fagotti, G. Ferrandina, F. Fanfani, G. Garganese, G. Vizzielli, and V. Carone Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma Am J Obstet Gynecol 199 6 Dec 2008 642.e1 642.e6
31. I. Vergote, I. De Wever, W. Tjalma, M. van Gramberen, J. Decloedt, and P. van Dam Interval debulking surgery: an alternative for primary surgical debulking? Sem Surg Oncol 19 2000 49 53
32. R.G. Moore, A.K. Brown, M.C. Miller, D. Badgwell, Z. Lu, and W.J. Allard Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus Gynecol Oncol 110 2 2008 196 201
33. R. Angioli, F. Plotti, S. Capriglione, R. Montera, P. Damiani, and R. Ricciardi The role of novel biomarker HE4 in endometrial cancer: a case control prospective study Tumour Biol Nov 20 2012 [Epub ahead of print] PubMed PMID: 23179397